Supriya Lifescience Gains 3.50% This Week: Key Technical Shifts and Volatility Insights

2 hours ago
share
Share Via
Supriya Lifescience Ltd closed the week ending 10 April 2026 with a 3.50% gain, rising from Rs.616.40 to Rs.637.95. Despite this positive move, the stock underperformed the Sensex, which advanced 5.34% over the same period. The week was marked by a significant gap up on 8 April, followed by mixed technical signals and notable volatility, reflecting a complex trading environment for this small-cap pharmaceutical stock.

Key Events This Week

6 Apr: Week opens at Rs.616.40

7 Apr: Stock dips 1.23% despite Sensex rising 0.50%

8 Apr: Strong gap up opening with 9.21% surge, intraday high Rs.664.85

9 Apr: Price retreats 1.10% amid mixed market signals

10 Apr: Week closes at Rs.637.95, up 1.43% on the day

Week Open
Rs.616.40
Week Close
Rs.637.95
+3.50%
Week High
Rs.664.85
vs Sensex
-1.84%

6 April 2026: Week Opens Steady at Rs.616.40

Supriya Lifescience Ltd began the week at Rs.616.40 on the BSE, with a modest volume of 3,917 shares traded. The Sensex closed at 33,229.93, setting a baseline for the week’s performance. The stock’s opening price was in line with recent trading levels, reflecting a neutral start ahead of anticipated market developments.

7 April 2026: Price Declines Amid Broader Market Gains

The stock declined by 1.23% to Rs.608.80, shedding Rs.7.60 from the previous close. This drop contrasted with the Sensex’s 0.50% gain to 33,395.05, indicating underperformance relative to the broader market. Trading volume increased slightly to 4,251 shares, suggesting cautious investor sentiment. The divergence between the stock and index hinted at sector-specific or company-related pressures.

8 April 2026: Significant Gap Up and Intraday Volatility

On 8 April, Supriya Lifescience Ltd opened sharply higher with a gap up of 9.21%, surging to an opening price near Rs.672. This strong start was supported by a robust intraday high of Rs.664.85, representing a 9.21% increase from the previous day’s close. The stock closed at Rs.635.95, up 4.46% on the day, marginally outperforming the Sensex’s 3.88% rise to 34,690.59.

This gap up reflected renewed buying interest and positive sentiment within the Pharmaceuticals & Biotechnology sector. Intraday volatility was elevated at 5.34%, indicating active trading and price fluctuations. Technical indicators showed the stock trading above its 5-day and 20-day moving averages, signalling short-term strength, although it remained below longer-term averages, suggesting caution.

Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!

  • - Highest rated stock selection
  • - Multi-parameter screening cleared
  • - Large Cap quality pick

View Our Top 1% Pick →

9 April 2026: Price Pulls Back Amid Mixed Technical Signals

The stock retreated by 1.10% to Rs.628.95, losing Rs.7.00 from the previous close. This decline occurred alongside a 0.49% drop in the Sensex to 34,521.99, indicating a broadly negative market tone. Volume decreased to 4,757 shares, reflecting reduced trading activity.

Technical analysis revealed a bearish shift, with the Moving Average Convergence Divergence (MACD) indicator turning bearish on the weekly timeframe and the Know Sure Thing (KST) oscillator also signalling weakness. Despite this, the Relative Strength Index (RSI) on the weekly chart remained bullish, suggesting potential for a short-term bounce. The stock hovered near its lower Bollinger Band, which may act as a support level.

10 April 2026: Week Closes with Modest Gain at Rs.637.95

Supriya Lifescience Ltd ended the week on a positive note, rising 1.43% to Rs.637.95 on increased volume of 7,458 shares. The Sensex also advanced 1.40% to 35,004.96, reflecting broad market strength. The stock’s weekly gain of 3.50% was respectable but lagged the Sensex’s 5.34% rise, underscoring relative underperformance.

Despite the week’s volatility and mixed technical signals, the stock maintained a position above its week’s opening price. The MarketsMOJO Mojo Score remains at 38.0 with a Sell grade, reflecting ongoing caution due to the stock’s small-cap status and recent technical deterioration.

Supriya Lifescience Ltd or something better? Our SwitchER feature analyzes this small-cap stock and recommends superior alternatives based on fundamentals, momentum, and value!

  • - SwitchER analysis complete
  • - Superior alternatives found
  • - Multi-parameter evaluation

See Smarter Alternatives →

Date Stock Price Day Change Sensex Day Change
2026-04-06 Rs.616.40 - 33,229.93 -
2026-04-07 Rs.608.80 -1.23% 33,395.05 +0.50%
2026-04-08 Rs.635.95 +4.46% 34,690.59 +3.88%
2026-04-09 Rs.628.95 -1.10% 34,521.99 -0.49%
2026-04-10 Rs.637.95 +1.43% 35,004.96 +1.40%

Key Takeaways

Supriya Lifescience Ltd’s week was characterised by a strong midweek rally, led by a significant gap up on 8 April that reflected positive market sentiment and sector outperformance. However, the stock’s inability to sustain gains fully and the subsequent pullback on 9 April highlighted underlying volatility and mixed technical momentum.

The technical landscape remains complex: while short-term indicators such as the weekly RSI suggest potential for rebounds, bearish signals from MACD, KST, and daily moving averages caution against overoptimism. The stock’s small-cap status and adjusted beta of 1.18 amplify its sensitivity to market swings, contributing to the observed price fluctuations.

MarketsMOJO’s downgrade to a Sell grade and a Mojo Score of 38.0 reinforce a cautious stance, signalling that fundamental and technical challenges persist despite intermittent strength. The stock’s weekly gain of 3.50% was respectable but lagged the Sensex’s 5.34% advance, indicating relative underperformance within the broader market context.

Investors should monitor key technical levels, including the 52-week low near Rs.565.00 and the stock’s position relative to moving averages, to gauge potential trend reversals or further downside risks. The week’s price action underscores the importance of balancing short-term momentum signals with longer-term caution in this volatile small-cap pharmaceutical stock.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News